Get the Stockscreener App
181.55
1.81%
-3.35
Biogen Inc stock is traded at $181.55, with a volume of 1.07M.
It is down -1.81% in the last 24 hours and down -7.62% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$184.90
Open:
$185.99
24h Volume:
1.07M
Relative Volume:
0.65
Market Cap:
$26.64B
Revenue:
$9.53B
Net Income/Loss:
$1.29B
P/E Ratio:
20.62
EPS:
8.8057
Net Cash Flow:
$1.97B
1W Performance:
-1.80%
1M Performance:
-7.62%
6M Performance:
+25.33%
1Y Performance:
+29.70%
1-Day Range:
$181.46
$188.00
1-Week Range:
$181.46
$192.99
52-Week Range:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
181.55 | 26.64B | 9.53B | 1.29B | 1.97B | 8.8057 |
|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Capula Management Ltd Takes $1.43 Million Position in Biogen Inc. $BIIB - MarketBeat
Does New Once-Yearly SMA Data And Phase 3 Plan Change The Bull Case For Biogen (BIIB)? - simplywall.st
Biogen CLO Retiring After 20 Years With Biopharma Biz - Law360
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference - Yahoo Finance
Assessing Biogen (BIIB) Valuation After Recent Shareholder Return Momentum - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy - Yahoo
Swiss National Bank Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander Effective May 2026 - Minichart
Biogen presents Phase 1b data on salanersen for SMA treatment - Investing.com South Africa
Biogen Announces Upcoming Departure of Chief Legal Officer - TipRanks
Biogen chief legal officer Susan H. Alexander to depart at end of May - Investing.com
Oppenheimer reiterates Biogen stock rating on SMA drug data By Investing.com - Investing.com Nigeria
Oppenheimer reiterates Biogen stock rating on SMA drug data - Investing.com
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026 - marketscreener.com
Biogen Unveils Phase III Salanersen Program To Bring Longer-Acting SMA Option - Citeline News & Insights
Biogen builds case for Spinraza successor with fresh data - BioPharma Dive
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? - Yahoo Finance
Biogen Settles Investors' $50M Claim Over Pain Drug Deal - Law360
Biogen presents additional salanersen data in SMA - The Pharmaletter
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock - Yahoo Finance
Biogen (BIIB) Reveals Promising Phase 1b Study Results for Salan - GuruFocus
Van ECK Associates Corp Has $149.46 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen presents new Phase 1b results for spinal muscular atrophy drug at MDA Conference - Traders Union
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy - Biogen
Biogen (WBO:BIIB) NonCurrent Deferred Revenue : €0 Mil (As of Dec. 2025) - GuruFocus
Biogen to Participate in the Stifel 2026 Virtual CNS Forum - Biogen
Therapeutics Sector Q4 2025 Earnings Review: Resilience and GrowthNews and Statistics - IndexBox
Causeway Capital Management LLC Acquires 74,163 Shares of Biogen Inc. $BIIB - MarketBeat
Jefferies Financial Group Inc. Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Down 36% intraday BIIB.SW Biogen Inc. (SIX) 09 Mar 2026: catalysts to track - Meyka
MDA 2026: Trio of trials now testing Spinraza successor salanersen for SMA - SMA News Today
Victory Capital Management Inc. Purchases 89,530 Shares of Biogen Inc. $BIIB - MarketBeat
Rhenman & Partners Asset Management AB Boosts Biogen Stake by 358% - National Today
Rhenman & Partners Asset Management AB Has $7.70 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen’s Dravet And SMA Advances Add Depth To Long Term Story - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts - MarketBeat
Biogen Inc (BIIB) Shares Gap Down to $181.74 on Mar 6 - GuruFocus
Health Rounds: Protein related to Parkinson's linked to faster Alzheimer's progression in women - marketscreener.com
Biogen/Stoke’s zorevunersen hailed as potential first disease-modifying drug for rare epilepsy - European Pharmaceutical Review
Spinal muscular atrophy research progresses at 2026 MDA Conference, Biogen asserts - Traders Union
What Makes Biogen (BIIB) an Attractive Long-Term Holding? - Insider Monkey
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences - Biogen
Biogen Inc Announces to Present New Data and Updates from Its Spinal Muscle Atrophy Research Programs - marketscreener.com
(BIIB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Mo - PharmiWeb.com
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):